Human anti Cetuximab, clone AbD19834_IgG1, is an anti-idiotypic antibody that binds specifically to cetuximab and inhibits the binding of the drug to its target, epidermal growth factor receptor (EGFR). It can be used in bioanalytical assays to measure the levels of cetuximab and biosimilar products in preclinical research and clinical trials.Human anti Cetuximab, clone AbD19834_IgG1 is a fully human antibody and is particularly suited as a calibrator for immune response assays to measure the anti-drug antibody (ADA) levels in patient sera.Cetuximab (brand name Erbitux®) is a chimeric monoclonal antibody drug (IgG1/kappa) approved for treatment of KRAS wild-type metastatic colorectal cancers and squamous cell carcinoma of the head and neck. This therapeutic antibody is directed against EGFR and inhibits tumor cell proliferation by blocking the interaction of epidermal growth factor (EGF) with its receptor.View a summary of all anti cetuximab antibodies.
- Product Form
- Human IgG1 antibody selected from the HuCAL® phage display library and expressed in a human cell line. This product is supplied as a liquid.
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.01% Thiomersal
- Immunogen
- Cetuximab.
- Affinity
- The monovalent intrinsic affinity of HCA222 was measured as KD = 0.5 nM by real time, label free molecular interaction analysis on immobilized cetuximab.
- Approx. Protein Concentrations
- IgG concentration 0.5 mg/ml
- Storage
- Store at +4oC or at -20oC if preferred.Storage in frost-free freezers is not recommended.This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
- Guarantee
- 12 months from date of despatch
- Acknowledgements
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.Erbitux® is a registered trademark of ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company.
- Licensed Use
- For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
- Regulatory
- For research purposes only
Applications of Cetuximab antibody
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.Application Name | Verified | Min Dilution | Max Dilution |
---|
ELISA | | | |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in theHuCAL Antibodies Technical Manual
- ELISA
- This product is suitable for use in direct ELISA applications or as a bridging reagent in ADA assays.Protocol: PK bridging ELISA to measure free drugProtocol: ADA bridging ELISA
Copyright © 2020 Bio-Rad Antibodies (formerly AbD Serotec)
Useful Reagents Available
Description | Product Code | Applications | Pack Size | Your Price | List Price | Quantity |
---|
Hispec Assay Diluent | BUF049A | E IY | 50 ml | Log in | | |
LYNX Rapid HRP Antibody Conjugation Kit | LNK002P | CJ | 3 Conjugations For 400µg Antibody | Log in | | |
Product Specific References
Further Reading
- Gomez, D. et al. (2013) Cetuximab therapy in the treatment of metastatic colorectal cancer: the future frontier?Int J Surg. 11 (7): 507-13.